Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients With Relapsed and/or Refractory Follicular Lymphoma After=2 Prior Therapies: 3-Year Follow-Up From a Pivotal Phase II Study

被引：0

作者：

Schuster, Stephen J. ^{[1
]}

Sehn, Laurie H. ^{[2
]}

Bartlett, Nancy L. ^{[3
]}

Matasar, Matthew ^{[4
]}

Assouline, Sarit ^{[5
]}

Giri, Pratyush ^{[6
]}

Kuruvilla, John ^{[7
]}

Shadman, Mazyar ^{[8
,9
]}

Cheah, Chan Y. ^{[10
,11
]}

Dietrich, Sascha ^{[12
]}

Fay, Keith ^{[13
,14
]}

Ku, Matthew ^{[15
]}

Nastoupil, Loretta ^{[16
]}

Wei, Michael C. ^{[17
]}

Yin, Shen ^{[17
]}

To, Iris ^{[17
]}

Huang, Jiangeng ^{[17
]}

Kwan, Antonia ^{[17
]}

Penuel, Elicia ^{[17
]}

Budde, L. Elizabeth ^{[18
]}

机构：

[1] Univ Penn, Lymphoma Program, Abramson Canc Ctr, Philadelphia, PA USA

[2] Univ British Columbia, BC Canc Ctr Lymphoid Canc, Vancouver, BC, Canada

[3] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO USA

[4] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA

[5] Jewish Gen Hosp, Montreal, PQ, Canada

[6] Royal Adelaide Hosp, Adelaide, Australia

[7] Princess Margaret Canc Ctr, Toronto, ON, Canada

[8] Fred Hutchinson Canc Res Ctr, Seattle, WA USA

[9] Univ Washington, Seattle, WA USA

[10] Sir Charles Gairdner Hosp, Linear Clin Res, Nedlands, Australia

[11] Univ Western Australia, Perth, Australia

[12] Heidelberg Univ, Heidelberg, Germany

[13] St Vincents Hosp, Sydney, Australia

[14] Royal North Shore Hosp, Sydney, Australia

[15] Univ Melbourne, St Vincents Hosp, Melbourne, Australia

[16] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[17] Genentech Inc, South San Francisco, CA USA

[18] City Hope Natl Med Ctr, Duarte, CA USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷

关键词：

IBCL; non-Hodgkin lymphoma; indolent lymphoma; follicular lymphoma; bispecific antibody;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

IBCL-335

引用

页码：S497 / S497

页数：1

共 50 条

[1] Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed and/or Refractory Follicular Lymphoma after=2 Prior Therapies: 3-Year Follow-up from a Pivotal Phase II Study
Schuster, Stephen J.
Sehn, Laurie H.
Bartlett, Nancy L.
Matasar, Matthew
Assouline, Sarit
Giri, Pratyush
Kuruvilla, John
Shadman, Mazyar
Cheah, Chan Y.
Dietrich, Sascha
Fay, Keith
Ku, Matthew
Nastoupil, Loretta J.
Wei, Michael C.
Yin, Shen
To, Iris
Huang, Jiangeng
Kwan, Antonia
Penuel, Elicia
Budde, L. Elizabeth
BLOOD, 2023, 142
[2] Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies
Sehn, Laurie H.
Bartlett, Nancy L.
Matasar, Matthew J.
Schuster, Stephen J.
Assouline, Sarit E.
Giri, Pratyush
Kuruvilla, John
Shadman, Mazyar
Cheah, Chan Yoon
Dietrich, Sascha
Fay, Keith
Ku, Matthew
Nastoupil, Loretta J.
Wei, Michael C.
Yin, Shen
To, Iris
Kaufman, Derrick
Kwan, Antonia
Penuel, Elicia
Bolen, Christopher R.
Budde, Lihua E.
BLOOD, 2025, 145 (07) : 708 - 719
[3] Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed/ refractory follicular lymphoma who received ≥2 prior therapies: updated results from a pivotal Phase II study
Dietrich, S.
Bartlett, N. L.
Sehn, L. H.
Matasar, M.
Schuster, S. J.
Assouline, S.
Giri, P.
Kuruvilla, J.
Canales, M.
Fay, K.
Ku, M.
Nastoupil, L.
Wie, M. C.
Yin, S.
To, I.
Huang, H.
Min, J.
Bolen, C. R.
Penuel, E.
Budde, L. E.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 211 - 212
[4] Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study
Bartlett, Nancy L.
Sehn, Laurie H.
Matasar, Matthew J.
Schuster, Stephen J.
Assouline, Sarit
Giri, Pratyush
Kuruvilla, John
Canales, Miguel
Dietrich, Sascha
Fay, Keith
Ku, Matthew
Nastoupil, Loretta J.
Wei, Michael C.
Yin, Shen
To, Iris
Huang, Huang
Min, Juliana
Penuel, Elicia
Budde, L. Elizabeth
BLOOD, 2022, 140 : 1467 - 1470
[5] Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/ Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study
Bartlett, Nancy L.
Sehn, Laurie H.
Matasar, Matthew J.
Schuster, Stephen J.
Assouline, Sarit E.
Giri, Pratyush
Kuruvilla, John
Canales, Miguel
Dietrich, Sascha
Fay, Keith
Ku, Matthew
Nastoupil, Loretta
Wei, Michael C.
Yin Shen
To, Iris
Huang Huang
Min, Juliana
Bolen, Christopher R.
Penuel, Eliciaand
Elizabeth, Budde L.
AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S44 - S44
[6] Mosunetuzumab Monotherapy Demonstrates Durable Efficacy With a Manageable Safety Profile in Patients With Relapsed/Refractory Follicular Lymphoma who Received ≥2 Prior Therapies: Updated Results From a Pivotal Phase II Study
Bartlett, Nancy L.
Sehn, Laurie H.
Matasar, Matthew
Schuster, Stephen J.
Assouline, Sarit
Giri, Pratyush
Kuruvilla, John
Canales, Miguel
Dietrich, Sascha
Fay, Keith
Ku, Matthew
Nastoupil, Loretta
Wei, Michael C.
Yin, Shen
To, Iris
Huang, Huang
Min, Juliana
Bolen, Christopher R.
Penuel, Elicia
Budde, L. Elizabeth
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S453 - S453
[7] Clinical Outcomes of Patients with Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 Elara 3-Year Follow-up
Schuster, Stephen J.
Fowler, Nathan
Dickinson, Michael
Martinez-Lopez, Joaquin
Kolstad, Arne
Butler, Jason
Ghosh, Monalisa
Popplewell, Leslie L.
Chavez, Julio C.
Bachy, Emmanuel
Kato, Koji
Harigae, Hideo
Kersten, Marie Jose
Andreadis, Charalambos
Riedell, Peter A.
Ho, Phoebe Joy
Perez-Simon, Jose A.
Chen, Andy
Nastoupil, Loretta J.
von Tresckow, Bastian
Ferreri, Andres Jose Maria
Teshima, Takanori
Patten, Piers
McGuirk, Joseph P.
Petzer, Andreas L.
Offner, Fritz
Viardot, Andreas
Zinzani, Pier Luigi
Malladi, Ram
Zia, Aiesha
Awasthi, Rakesh
Paule, Ines
Germano, Davide
Ramos, Roberto Javier
Hsu, Pei
Thieblemont, Catherine
Dreyling, Martin
BLOOD, 2023, 142
[8] Mosunetuzumab Monotherapy is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory Follicular Lymphoma who have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study
Budde, Elizabeth
Sehn, Laurie H.
Matasar, Matthew
Schuster, Stephen J.
Assouline, Sarit
Giri, Pratyush
Kuruvilla, John
Canales, Miguel
Dietrich, Sascha
Fay, Keith
Ku, Matthew
Nastoupil, Loretta
Wei, Michael C.
Yin, Shen
Doral, Michelle Y.
Li, Chi-Chung
Huang, Huang
Negricea, Raluca
Penuel, Elicia
O'Hear, Carol
Bartlett, Nancy L.
El-Sharkawi, Dima
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 18 - 20
[9] Clinical Outcomes of Patients With Relapsed/Refractory Follicular Lymphoma (R/R FL) Treated With Tisagenlecleucel: Phase 2 ELARA 3-Year Follow-Up
Schuster, Stephen J.
Fowler, Nathan Hale
Dickinson, Michael
Martinez-Lopez, Joaquin
Kolstad, Arne
Butler, Jason
Ghosh, Monalisa
Popplewell, Leslie
Chavez, Julio C.
Bachy, Emmanuel
Kato, Koji
Harigae, Hideo
Kersten, Marie Jose
Andreadis, Charalambos
Riedell, Peter A.
Ho, P. Joy
Perez-Simon, Jose Antonio
Chen, Andy I.
Nastoupil, Loretta J.
von Tresckow, Bastian
Ferreri, Andres Jose Maria
Teshima, Takanori
Patten, Piers E. M.
McGuirk, Joseph P.
Petzer, Andreas L.
Offner, Fritz
Viardot, Andreas
Zinzani, Pier Luigi
Malladi, Ram
Zia, Aiesha
Awasthi, Rakesh
Paule, Ines
Germano, Davide
Ramos, Roberto
Hsu, Pei
Thieblemont, Catherine
Dreyling, Martin
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S495 - S496
[10] Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study
Budde, L. Elizabeth
Sehn, Laurie H.
Matasar, Matthew J.
Schuster, Stephen J.
Assouline, Sarit
Giri, Pratyush
Kuruvilla, John
Canales, Miguel
Dietrich, Sascha
Fay, Keith
Ku, Matthew
Nastoupil, Loretta
Wei, Michael C.
Yin, Shen
Doral, Michelle Y.
Li, Chi-Chung
Huang, Huang
Negricea, Raluca
Penuel, Elicia
O'Hear, Carol
Bartlett, Nancy L.
BLOOD, 2021, 138

← 1 2 3 4 5 →